BioSante Pharmaceuticals has brought in Deutsche Bank to advise the company on its "strategic alternatives." The developer has advanced LibiGel, a topical therapy for female sexual dysfunction, into a late stage trial. BioSante has told investors that it hopes to gain an FDA approval on the treatment by 2010.
News of the Deutsche Bank move helped buoy shares of BioSante. The company announced in March that it had begun a Phase III trial on LibiGel.
- read the AP report [1]
Related Articles:
The Biotech Haunted House [2]
BioSante reports adjuvant success [3]
Links:
[1] http://money.cnn.com/news/newsfeeds/articles/apwire/42ed473aa5d932c8eaaa976d4d878fe0.htm
[2] http://www.fiercebiotech.com/story/the-biotech-haunted-house/2006-11-03
[3] http://www.fiercebiotech.com/story/spotlight-biosante-reports-adjuvant-success/2006-04-24?utm_medium=rss&utm_source=rss&cmp-id=OTC-RSS-FB0